Literature DB >> 31384108

Novel Therapeutic Approaches of Pulmonary Arterial Hypertension.

Sanjay Tyagi1,2, Vishal Batra2.   

Abstract

Pulmonary arterial hypertension (PAH) is an uncommon disease characterized progressive remodeling of pulmonary vasculature. Although treatment for PAH have improved in last two decades but the outcome remains fatal. Currently, the therapies for PAH target three well-established pathways the nitric oxide (NO) pathway, endothelin receptors, and prostanoids. There are multiple potential targets for development of newer drugs in PAH which requires meticulous research and clinical trials.

Entities:  

Keywords:  endothelin receptor; nitric oxide; novel; phosphodiesterase; prostaglandins; pulmonary arterial hypertension; therapeutic

Year:  2019        PMID： 31384108      PMCID： PMC6679998          DOI： 10.1055/s-0039-1692140

Source DB:  PubMed          Journal:  Int J Angiol        ISSN： 1061-1711


  45 in total

1.  Sildenafil citrate therapy for pulmonary arterial hypertension.

Authors:  Nazzareno Galiè; Hossein A Ghofrani; Adam Torbicki; Robyn J Barst; Lewis J Rubin; David Badesch; Thomas Fleming; Tamiza Parpia; Gary Burgess; Angelo Branzi; Friedrich Grimminger; Marcin Kurzyna; Gérald Simonneau
Journal:  N Engl J Med       Date:  2005-11-17       Impact factor: 91.245

2.  Effects of beraprost sodium, an oral prostacyclin analogue, in patients with pulmonary arterial hypertension: a randomized, double-blind, placebo-controlled trial.

Authors:  Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiéry; Carmine Dario Vizza; Meinhard Kneussl; Alessandra Manes; Olivier Sitbon; Adam Torbicki; Marion Delcroix; Robert Naeije; Marius Hoeper; Ari Chaouat; Sophie Morand; Bruno Besse; Gerald Simonneau
Journal:  J Am Coll Cardiol       Date:  2002-05-01       Impact factor: 24.094

3.  Ambrisentan therapy for pulmonary arterial hypertension.

Authors:  Nazzareno Galié; David Badesch; Ronald Oudiz; Gérald Simonneau; Michael D McGoon; Anne M Keogh; Adaani E Frost; Diane Zwicke; Robert Naeije; Shelley Shapiro; Horst Olschewski; Lewis J Rubin
Journal:  J Am Coll Cardiol       Date:  2005-08-02       Impact factor: 24.094

4.  Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial.

Authors:  Gerald Simonneau; Robyn J Barst; Nazzareno Galie; Robert Naeije; Stuart Rich; Robert C Bourge; Anne Keogh; Ronald Oudiz; Adaani Frost; Shelmer D Blackburn; James W Crow; Lewis J Rubin
Journal:  Am J Respir Crit Care Med       Date:  2002-03-15       Impact factor: 21.405

5.  An antiproliferative BMP-2/PPARgamma/apoE axis in human and murine SMCs and its role in pulmonary hypertension.

Authors:  Georg Hansmann; Vinicio A de Jesus Perez; Tero-Pekka Alastalo; Cristina M Alvira; Christophe Guignabert; Janine M Bekker; Stefan Schellong; Takashi Urashima; Lingli Wang; Nicholas W Morrell; Marlene Rabinovitch
Journal:  J Clin Invest       Date:  2008-05       Impact factor: 14.808

6.  Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist.

Authors:  Marc Iglarz; Christoph Binkert; Keith Morrison; Walter Fischli; John Gatfield; Alexander Treiber; Thomas Weller; Martin H Bolli; Christoph Boss; Stephan Buchmann; Bruno Capeleto; Patrick Hess; Changbin Qiu; Martine Clozel
Journal:  J Pharmacol Exp Ther       Date:  2008-09-09       Impact factor: 4.030

7.  Circulating endothelial progenitor cells in patients with Eisenmenger syndrome and idiopathic pulmonary arterial hypertension.

Authors:  Gerhard-Paul Diller; Sven van Eijl; Darlington O Okonko; Luke S Howard; Omar Ali; Thomas Thum; Stephen J Wort; Elisabeth Bédard; J Simon R Gibbs; Johann Bauersachs; Adrian J Hobbs; Martin R Wilkins; Michael A Gatzoulis; John Wharton
Journal:  Circulation       Date:  2008-06-02       Impact factor: 29.690

8.  Beraprost therapy for pulmonary arterial hypertension.

Authors:  Robyn J Barst; Michael McGoon; Vallerie McLaughlin; Victor Tapson; Stuart Rich; Lewis Rubin; Karlman Wasserman; Ronald Oudiz; Shelley Shapiro; Ivan M Robbins; Richard Channick; David Badesch; Barry K Rayburn; Robin Flinchbaugh; Jeff Sigman; Carl Arneson; Roger Jeffs
Journal:  J Am Coll Cardiol       Date:  2003-06-18       Impact factor: 24.094

Review 9.  Evidence-based pharmacologic management of pulmonary arterial hypertension.

Authors:  Neal Benedict; Amy Seybert; Michael A Mathier
Journal:  Clin Ther       Date:  2007-10       Impact factor: 3.393

10.  Inhaled iloprost for severe pulmonary hypertension.

Authors:  Horst Olschewski; Gerald Simonneau; Nazzareno Galiè; Timothy Higenbottam; Robert Naeije; Lewis J Rubin; Sylvia Nikkho; Rudolf Speich; Marius M Hoeper; Jürgen Behr; Jörg Winkler; Olivier Sitbon; Wladimir Popov; H Ardeschir Ghofrani; Alessandra Manes; David G Kiely; Ralph Ewert; Andreas Meyer; Paul A Corris; Marion Delcroix; Miguel Gomez-Sanchez; Harald Siedentop; Werner Seeger
Journal:  N Engl J Med       Date:  2002-08-01       Impact factor: 91.245
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.